TOKYO, MUNICH and BASKING RIDGE, N.J., Sept. 9, 2019 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the submission of a New Drug Application (NDA) to Japan's Ministry of Health, Labour and Welfare (MHLW) for the use of [fam-

SAN DIEGO, Sept. 9, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the developmen

SAN DIEGO, Sept. 9, 2019 /PRNewswire/ -- Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients wi

SALT LAKE CITY, Sept. 9, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that an abstract with data from 15 patient cases where the Company's SkinTE™ product was used to treat a variety of wounds was accepted for a podium prese

AYER, Mass., Sept. 9, 2019 /PRNewswire/ -- The registered nurses at Steward Nashoba Valley Medical Center (NVMC) in Ayer, who are represented by the Massachusetts Nurses Association (MNA), have filed  unfair labor practice charges at the U.S. National Labor Relations Board (NLRB) against the Dallas-ba

HOUSTON, Sept. 9, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced the issuance of a letter to shareholders from the Company.

ANKENY, Iowa, Sept. 9, 2019 /PRNewswire/ -- Proliant Biologicals, LLC (Proliant), an LGI company (Lauridsen Group Inc.), today announced that it has acquired Boval BioSolutions from Lifecycle Biotechnologies of Fort Worth, TX. The acquisition concluded on September 2, 2019 and financial terms of the deal

RIDGEFIELD, Conn., Sept. 9, 2019 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved Ofev® (nintedanib) as the first and only medicine to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Ofev is already approved in th

BIRMINGHAM, Ala., Sept. 9, 2019 /PRNewswire/ -- Encompass Health Corporation (NYSE: EHC) today announced it has commenced a public offering of $800 million in aggregate principal amount of senior notes. The notes are to be issued in two series, one maturing in 2028 and the other in 2030. The Company intends to use the net proceeds from this

SAN FRANCISCO, Sept. 9, 2019 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the availability of Detect Hereditary Pancreatic Cancer, a te